Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17937424 | 0.97 | — | — | |
| SCHEMBL24797747 | 0.92 | — | — | |
| SCHEMBL15695397 | 0.85 | — | — | |
| SCHEMBL296484 | 0.77 | CA1 (0.38) | CA1CA12CA7CA14CA2 | |
| SCHEMBL11563645 | 0.77 | CA1 (0.38) | CA1CA12CA7CA14CA2 | |
| SCHEMBL20170452 | 0.77 | CA1 (0.38) | CA1CA12CA7CA14CA2 | |
| SCHEMBL20170489 | 0.77 | CA1 (0.38) | CA1CA12CA7CA14CA2 | |
| SCHEMBL18136569 | 0.77 | CA1 (0.38) | CA1CA12CA7CA14CA2 | |
| SCHEMBL780033 | 0.77 | CA1 (0.38) | CA1CA12CA7CA14CA2 | |
| SCHEMBL15508205 | 0.77 | CA1 (0.38) | CA1CA12CA7CA14CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503446-B2 | Bromodomain inhibitors | Forschungszentrum Jülich GmbH (DE) | 2025-12-23 | — | — | US | disclosed |
| US-20220372004-A1 | BROMODOMAIN INHIBITORS | Forschungszentrum Jülich GmbH (DE) | 2022-11-24 | — | — | US | disclosed |
| EP-4051383-A1 | BROMODOMAIN INHIBITORS | Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen (DE) | 2022-09-07 | — | — | EP | disclosed |
| WO-2021083879-A1 | BROMODOMAIN INHIBITORS | RHEINISCH-WESTFÄLISCHE TECHNISCHE HOCHSCHULE (RWTH) AACHEN (DE) | 2021-05-06 | — | — | WO | disclosed |
| US-8003787-B2 | Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003787-B2 | Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003787-B2 | Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-23 | — | — | US | disclosed |
| EP-2152672-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINAZOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-02-17 | — | — | EP | disclosed |
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER HEALTHCARE LLC (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER HEALTHCARE LLC (DE) | 2009-09-10 | — | — | US | disclosed |
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER HEALTHCARE LLC (DE) | 2009-09-10 | — | — | US | disclosed |
| WO-2008141843-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINAZOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008141843-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINAZOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MAP4K2, MAP3K20, MAP3K2 | CA1 4102/4885CA12 4595/4885CA7 4103/4885 |
| US-20220372004-A1 | BROMODOMAIN INHIBITORS | BRDT, BRD4, BRPF3 | CA1 4251/4885CA12 4233/4885CA7 4654/4885 |
| US-12503446-B2 | Bromodomain inhibitors | BRDT, BRD4, BRPF3 | CA1 4251/4885CA12 4233/4885CA7 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.